ASH 2022 | The importance of molecular characterization and precision medicine in AML
Claudio Cerchione
• 12 Dec 2022
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the importance of molecular characterization in acute myeloid leukemia (AML), highlighting findings from the AGILE trial (NCT03173248). Dr Cerchione suggests that molecular screening of patients is valuable and allows a transition to more targeted treatment approaches. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
